BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 29281732)

  • 1. Association of papillomavirus E6 proteins with either MAML1 or E6AP clusters E6 proteins by structure, function, and evolutionary relatedness.
    Brimer N; Drews CM; Vande Pol SB
    PLoS Pathog; 2017 Dec; 13(12):e1006781. PubMed ID: 29281732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple regions of E6AP (UBE3A) contribute to interaction with papillomavirus E6 proteins and the activation of ubiquitin ligase activity.
    Drews CM; Brimer N; Vande Pol SB
    PLoS Pathog; 2020 Jan; 16(1):e1008295. PubMed ID: 31971989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of High-Risk Papillomavirus 31 E6 Oncogenic Protein and Characterization of E6/E6AP/p53 Complex Formation.
    Conrady MC; Suarez I; Gogl G; Frecot DI; Bonhoure A; Kostmann C; Cousido-Siah A; Mitschler A; Lim J; Masson M; Iftner T; Stubenrauch F; Travé G; Simon C
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E6 proteins from high-risk HPV, low-risk HPV, and animal papillomaviruses activate the Wnt/β-catenin pathway through E6AP-dependent degradation of NHERF1.
    Drews CM; Case S; Vande Pol SB
    PLoS Pathog; 2019 Apr; 15(4):e1007575. PubMed ID: 31002735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
    Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
    Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic analysis of the interactions of human papillomavirus E6 oncoproteins with the ubiquitin ligase E6AP using surface plasmon resonance.
    Zanier K; Charbonnier S; Baltzinger M; Nominé Y; Altschuh D; Travé G
    J Mol Biol; 2005 Jun; 349(2):401-12. PubMed ID: 15890204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The stability of the human papillomavirus E6 oncoprotein is E6AP dependent.
    Tomaić V; Pim D; Banks L
    Virology; 2009 Oct; 393(1):7-10. PubMed ID: 19700180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAML1-induced HPV E6 oncoprotein stability is required for cellular proliferation and migration of cervical tumor-derived cells.
    Skelin J; Đukić A; Filić V; Hufbauer M; Akgül B; Thomas M; Banks L; Tomaić V
    J Med Virol; 2023 Mar; 95(3):e28624. PubMed ID: 36852660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of E6AP-independent degradation targets of HPV E6.
    Vats A; Thatte J; Banks L
    J Gen Virol; 2019 Dec; 100(12):1674-1679. PubMed ID: 31609195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Papillomavirus 16 (HPV-16), HPV-18, and HPV-31 E6 Override the Normal Phosphoregulation of E6AP Enzymatic Activity.
    Thatte J; Banks L
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping the interactome of HPV E6 and E7 oncoproteins with the ubiquitin-proteasome system.
    Poirson J; Biquand E; Straub ML; Cassonnet P; Nominé Y; Jones L; van der Werf S; Travé G; Zanier K; Jacob Y; Demeret C; Masson M
    FEBS J; 2017 Oct; 284(19):3171-3201. PubMed ID: 28786561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins.
    Zanier K; Charbonnier S; Sidi AO; McEwen AG; Ferrario MG; Poussin-Courmontagne P; Cura V; Brimer N; Babah KO; Ansari T; Muller I; Stote RH; Cavarelli J; Vande Pol S; Travé G
    Science; 2013 Feb; 339(6120):694-8. PubMed ID: 23393263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous papillomavirus E6 oncoproteins associate with MAML1 to repress transactivation and NOTCH signaling.
    Brimer N; Lyons C; Wallberg AE; Vande Pol SB
    Oncogene; 2012 Oct; 31(43):4639-46. PubMed ID: 22249263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53.
    Cooper B; Schneider S; Bohl J; Jiang Yh; Beaudet A; Vande Pol S
    Virology; 2003 Feb; 306(1):87-99. PubMed ID: 12620801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase.
    Kao WH; Beaudenon SL; Talis AL; Huibregtse JM; Howley PM
    J Virol; 2000 Jul; 74(14):6408-17. PubMed ID: 10864652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of E6AP (UBE3A) with human papillomavirus type 11 E6 protein.
    Brimer N; Lyons C; Vande Pol SB
    Virology; 2007 Feb; 358(2):303-10. PubMed ID: 17023019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A ubiquitin variant-based affinity approach selectively identifies substrates of the ubiquitin ligase E6AP in complex with HPV-11 E6 or HPV-16 E6.
    Ebner FA; Sailer C; Eichbichler D; Jansen J; Sladewska-Marquardt A; Stengel F; Scheffner M
    J Biol Chem; 2020 Oct; 295(44):15070-15082. PubMed ID: 32855237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6.
    Zanier K; Stutz C; Kintscher S; Reinz E; Sehr P; Bulkescher J; Hoppe-Seyler K; Travé G; Hoppe-Seyler F
    PLoS One; 2014; 9(11):e112514. PubMed ID: 25383876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein.
    Liu X; Yuan H; Fu B; Disbrow GL; Apolinario T; Tomaic V; Kelley ML; Baker CC; Huibregtse J; Schlegel R
    J Biol Chem; 2005 Mar; 280(11):10807-16. PubMed ID: 15655249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6.
    Lagrange M; Charbonnier S; Orfanoudakis G; Robinson P; Zanier K; Masson M; Lutz Y; Trave G; Weiss E; Deryckere F
    J Gen Virol; 2005 Apr; 86(Pt 4):1001-1007. PubMed ID: 15784893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.